Perioperative Nivolumab in Resectable Lung Cancer.
Tina CasconeMark M AwadJonathan D SpicerJie HeShun LuBoris SepesiFumihiro TanakaJanis M TaubeRobin CornelissenLibor HavelNina KarasevaJaroslaw KuzdzalLubos B PetruzelkaLin WuJean-Louis PujolHiroyuki ItoTudor-Eliade CiuleanuLudmila de Oliveira Muniz KochAnnelies JanssensAurelia AlexandruSabine BohnetFedor V MoiseyenkoYang GaoYasutaka WatanabeCinthya Coronado ErdmannPadma SathyanarayanaStephanie Meadows-ShropshireSteven I BlumMariano Provencio Pullanull nullPublished in: The New England journal of medicine (2024)
Perioperative treatment with nivolumab resulted in significantly longer event-free survival than chemotherapy in patients with resectable NSCLC. No new safety signals were observed. (Funded by Bristol Myers Squibb; CheckMate 77T ClinicalTrials.gov number, NCT04025879.).